Classification of primary immunodeficiencies as a reflection of modern ideas about their pathogenesis and therapeutic approaches
https://doi.org/10.17650/2311-1267-2017-4-3-51-57
Abstract
Primary immune deficiencies (PID) are the heterogeneous group of genetically associated disorders developed due to defects of more than 300 different genes. Modern classification of PID based on main pathogenic mechanism of disease, but to a large extent relies on presence of any genetic defect. Thus, role of molecular and genetic methods of investigation of patients comes to the fore and often determines approaches to a target conservative or curative therapy of PIDs. Despite of successful application of new therapeutic approaches, therapy with the help of intravenous immune globulins remains actual for majority of patients with PID.
About the Authors
N. B. Kuzmenko
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997, Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997, Russia
A. Yu. Shcherbina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997, Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997, Russia
References
1. Иммунология детского возраста. Практическое руководство по детским болезням. Под ред. А.Ю. Щербины и Е.Д. Пашанова. М.: Медпрактика-М, 2006. [Childhood Immunology. A practical guide to children’s illnesses. Ed.: A.Yu. Shcherbina, Ye.D. Pashanov. M.: Medpraktika-M, 2006. (In Russ.)].
2. Mahlaoui N., Warnatz K., Jones A., Workman S., Cant A. Advances in the Care of Primary Immunodeficiencies (PIDs): from Birth to Adulthood. J Clin Immunol 2017;37(5):452–60. doi: 10.1007/s10875-017- 0401-y.
3. Швец О.В., Продеус А.П., Щербина А.Ю. Синдром делеции del22q 11.2 (Синдром ДиДжорджи): клинические и иммунологические аспекты патологии. Российский иммунологический журнал 2011;2(14): 101–11. [Shvets O.V., Prodeus A.P., Shcherbina A.Yu. Clinical and immunological aspects of del 22q11.2 syndrome (Digeorge Syndrome). Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology 2011;2(14):101–11. (In Russ.)].
4. Winkelstein J.A., Marino M.C., Lederman H.M. et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006;85(4):193–202. doi: 10.1097/01.md.0000229482.27398.ad.
5. Church A.C. X-linked severe combined immunodeficiency. Hosp Med 2002;63(11):676– 80. PMID: 12474613.
6. Ochs H.D., Hitzig W.H. History of primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol 2012;12(6):577–87. doi: 10.1097/ACI.0b013e32835923a6.
7. Bruton O.C., Apt L., Gitlin D., Janeway C.A. Absense of serum gamma globulins. AMA Am J Dis Child 1952;84(5):632–6. PMID: 12984834.
8. Hinman J., Tullis J.L., Saravis C.A., Pennell R.B. Intravenous use of plasmin treated immunoglobulin G. I. Preliminary report on tolerance by immunologically deficient patients. Vox Sang 1967;13(1):85–90. PMID: 4166594.
9. Gatti R.A., Meuwissen H.J., Allen H.D., Hong R., Good R.A. Immunological reconstitution of sex linked lymphopenic immunological deficiency. Lancet 1968;2(7583):1366–9. PMID: 4177932.
10. ESID Registry. Working definitions for clinical diagnosis of PID. https://esid.org/ Working-Parties/Clinical/Resources/Diagnostic-criteria-for-PID2.
11. Orkin S.H., Daddona P.E., Shewach D.S. et al. Molecular cloning of human adenosine deaminase gene sequences. J Biol Chem 1983;258(21):12753–6. PMID: 6688808.
12. Takeshita T., Asao H., Ohtani K. et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992;257(5068):379– 82. PMID: 1631559.
13. Vetrie D., Vorechovský I., Sideras P. et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361(6409):226–33. doi: 10.1038/361226a0.
14. Bousfiha A., Jeddane L., Al-Herz W. et al. The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol 2015;35(8):727–38. doi: 10.1007/s10875- 015-0198-5.
15. Qamar N., Fuleihan R.L. The hyper IgM syndromes. Clin Rev Allergy Immunol 2014;46(2):120–30. doi: 10.1007/s12016- 013-8378-7.
16. Boisson B., Quartier P., Casanova J.L. Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind. Curr Opin Immunol 2015;32:90–105. doi: 10.1016/j. coi.2015.01.005.
17. Lucas M., Lee M., Lortan J. et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125(6):1354–60.e4. doi: 10.1016/j.jaci.2010.02.040.
18. Orange J.S., Grossman W.J., Navickis R.J., Wilkes M.M. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010;137(1):21–30. doi: 10.1016/j.clim.2010.06.012.
19. Смирнова И.Н., Родина Ю.А., Дерипапа Е.В. и др. Фармакоэкономический анализ заместительной терапии внутривенными иммуноглобулинами у пациентов с первичными дефектами гуморального звена иммунитета. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии 2016;15(1):66–71. [Smirnova I.N., Rodina Yu.A., Deripapa E.V. et al. Pharmacoeconomic analysis of intravenous immunoglobulin replacement therapy in patients with primary humoral immunodeficiencies. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/ Oncology and Immunopathology 2016;15(1):66–71. (In Russ.)].
20. Resnick E.S., Moshier E.L., Godbold J.H., Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012;119(7):1650–7. doi: 10.1182/blood-2011-09-377945.
21. Lopez-Herrera G., Tampella G., Pan-Hammarström Q. et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 2012;90(6):986–1001. doi: 10.1016/j.ajhg.2012.04.015.
22. Lucas C.L., Kuehn H.S., Zhao F. et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 2014;15(1):88–97. doi: 10.1038/ni.2771.
23. Schubert D., Bode C., Kenefeck R. et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014;20(12):1410–6. doi: 10.1038/ nm.3746.
24. Lo B., Zhang K., Lu W. et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 2015;349(6246):436–40. doi: 10.1126/science. aaa1663.
25. Vignesh P., Rawat A., Singh S. An Update on the Use of Immunomodulators in Primary Immunodeficiencies. Clin Rev Allergy Immunol 2017;52(2):287–303. doi: 10.1007/s12016- 016-8591-2. 26. http://pids.clin-reg.ru/
Review
For citations:
Kuzmenko N.B., Shcherbina A.Yu. Classification of primary immunodeficiencies as a reflection of modern ideas about their pathogenesis and therapeutic approaches. Russian Journal of Pediatric Hematology and Oncology. 2017;4(3):51-57. (In Russ.) https://doi.org/10.17650/2311-1267-2017-4-3-51-57
Views:
1781
Email this article 